Skip to main content
Premium Trial:

Request an Annual Quote

GenomeDx, Janssen Partner to Test Tumor Genome Profile Database

NEW YORK (GenomeWeb) – GenomeDx said today that it has signed an agreement to test its Decipher GRID database of cancer genomic profiles with samples from prostate cancer clinical trials run by Janssen Pharmaceuticals.

Under the terms of the deal, GenomeDx will test the samples in order to evaluate the association of prognostic and predictive genomic signatures from the Decipher GRID platform — which includes more than 40,000 RNA expression profiles of urologic cancers — with clinical outcomes.

Additional terms were not disclosed.

"We are excited to work together with Janssen on this important research collaboration, which we believe will accelerate the discovery and development of genomic solutions for the treatment and management of high-risk prostate cancer," GenomeDx President and CSO Elai Davicioni said in a statement. "Using Decipher and GRID to leverage the knowledge derived from thousands of tumor genomic profiles to uncover novel predictors of treatment response with machine learning approaches will help realize our mutual goal of personalizing therapy for men suffering from this disease."

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.